William Blair Analysts Lift Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Equities researchers at William Blair upped their Q2 2025 earnings per share estimates for Biogen in a report released on Wednesday, February 12th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings of $4.20 per share for the quarter, up from their previous estimate of $3.79. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share. William Blair also issued estimates for Biogen’s Q1 2026 earnings at $3.86 EPS, Q2 2026 earnings at $4.31 EPS, FY2026 earnings at $15.20 EPS and FY2028 earnings at $18.33 EPS.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.81%.

A number of other research firms also recently weighed in on BIIB. Stifel Nicolaus downgraded Biogen from a “buy” rating to a “hold” rating and set a $175.00 target price for the company. in a research report on Monday, December 16th. Morgan Stanley dropped their price target on Biogen from $192.00 to $157.00 and set an “equal weight” rating on the stock in a report on Thursday, February 13th. Jefferies Financial Group cut Biogen from a “buy” rating to a “hold” rating and dropped their price target for the company from $250.00 to $180.00 in a report on Monday, December 9th. Sanford C. Bernstein started coverage on Biogen in a report on Tuesday, February 11th. They issued a “market perform” rating and a $160.00 price target on the stock. Finally, Truist Financial dropped their price target on Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $211.85.

Biogen Stock Performance

BIIB opened at $136.57 on Monday. The company has a market capitalization of $19.90 billion, a price-to-earnings ratio of 12.34, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. Biogen has a 1-year low of $128.51 and a 1-year high of $238.00. The business has a 50 day moving average price of $146.52 and a two-hundred day moving average price of $172.19.

Institutional Trading of Biogen

A number of institutional investors have recently added to or reduced their stakes in the business. Vise Technologies Inc. acquired a new position in shares of Biogen during the 4th quarter worth $250,000. Inspire Trust Co. N.A. increased its stake in shares of Biogen by 12.8% during the 4th quarter. Inspire Trust Co. N.A. now owns 12,300 shares of the biotechnology company’s stock worth $1,881,000 after purchasing an additional 1,400 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Biogen by 33.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,533,813 shares of the biotechnology company’s stock worth $234,551,000 after purchasing an additional 381,122 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in shares of Biogen during the 4th quarter worth $23,195,000. Finally, Worldquant Millennium Advisors LLC increased its stake in shares of Biogen by 214.9% during the 4th quarter. Worldquant Millennium Advisors LLC now owns 461,120 shares of the biotechnology company’s stock worth $70,514,000 after purchasing an additional 314,669 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.